Friday, September 18, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Trialssemaglutidewegovyobesityfrance

French cohort SEMAFOLLOW to track weight trajectories after semaglutide 2.4 mg

Nantes University Hospital's observational national study follows patients treated under France's temporary authorisation and early access programme for Wegovy.

PR
By Priya Raman · Science Reporter
Sep 18 08:00 ETSource: ClinicalTrials.gov

The wire

  1. 01The not-yet-recruiting observational cohort (NCT07423481) starts October 1, 2026, and will assess weight change, treatment strategies and well-being across French specialist obesity centres.
  2. 02Real-world follow-up in grade 3 and complicated obesity speaks to questions clinicians face about who sustains response after early-access semaglutide.
  3. 03Enrollment size is not stated in the registration and no results timeline is given; observational design cannot establish causality.

From the source

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

NCT07423481 · N/A · NOT YET RECRUITING · Sponsor: Nantes University Hospital · Conditions: Obesity & Overweight.

Read at clinicaltrials.gov
Source URL https://clinicaltrials.gov/study/NCT07423481